BioCorRx Inc. announced that it has entered into a securities purchase agreement with with an accredited investor to issue a 8% convertible promissory note at a purchase price of $200,000 in the original principal amount of $220,000 and a common stock purchase warrant for 200,000 shares of its common stock, par value $0.001 per share and 24,000 restricted shares of common stock for the gross proceeds of $200,000 on December 8, 2023. The note will mature on September 8, 2024. The note may be prepaid at any time without penalty.

The note bears a one-time interest charge of 8% that was applied to the original principal amount on the note issuance date. The note is not secured by any collateral or any assets pledged to the investor. The note is converted into common stock at the conversion price provided the equity conditions are satisfied.

The warrant is exercisable for 4 years from the date of issuance at an exercise price of $2 per share.